U.S. Brain Tumor Market (2025 - 2034) Size, Share & Trends Analysis Report By Tumor Type (Malignant, Non-malignant), By Treatment Type (Surgery, Radiation Therapy, Interventional Device-Based Procedures, Chemotherapy), And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Research Methodology
                    1.3. Information Procurement
                        1.3.1. Purchased database
                        1.3.2. GVR’s internal database
                        1.3.3. Secondary sources
                        1.3.4. Primary research
                        1.3.5. Details of primary research in the U.S.
                    1.4. Information or Data Analysis
                        1.4.1. Data analysis models
                    1.5. Market Formulation & Validation
                    1.6. Model Details
                        1.6.1. Commodity flow analysis (Model 1)
                            1.6.1.1. Approach 1: Commodity flow approach
                        1.6.2. Volume price analysis (Model 2)
                            1.6.2.1. Approach 2: Volume price analysis
                    1.7. List of Secondary Sources
                    1.8. List of Primary Sources
                    1.9. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                        2.2.1. Tumor Type outlook
                        2.2.2. Treatment Type outlook
                    2.3. Competitive Insights
Chapter 3. U.S. Brain Tumor Market Variables, Trends & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent market outlook
                        3.1.2. Related/ancillary market outlook
                    3.2. Market Dynamics
                        3.2.1. Market driver analysis
                            3.2.1.1. Rising prevalence of primary and secondary brain tumors
                            3.2.1.2. Innovations in diagnostic imaging, surgical techniques (such as advanced neurosurgery), and therapeutic modalities (such as targeted therapies, immunotherapies, and radiotherapy)
                            3.2.1.3. Increasing awareness and early diagnosis of brain tumor
                        3.2.2. Market restraint analysis
                            3.2.2.1. High treatment costs
                            3.2.2.2. Side effects and complications associated with brain tumor treatrment
                        3.2.3. Market opportunity analysis
                            3.2.3.1. Increasing number of clinical trials
                            3.2.3.2. Rising fundings and investments from both public and private sectors in research and development activities
                        3.2.4. Market challenge analysis
                            3.2.4.1. Product recalls
                            3.2.4.2. Stringent regulations
                    3.3. U.S. Brain tumor Market Analysis Tools
                        3.3.1. Industry Analysis - Porter’s
                            3.3.1.1. Supplier power
                            3.3.1.2. Buyer power
                            3.3.1.3. Substitution threat
                            3.3.1.4. Threat of new entrant
                            3.3.1.5. Competitive rivalry
                        3.3.2. PESTEL Analysis
                            3.3.2.1. Political landscape
                            3.3.2.2. Technological landscape
                            3.3.2.3. Economic landscape
Chapter 4. U.S. Brain Tumor Market: Tumor Type Estimates & Trend Analysis
                    4.1. Definitions and Scope
                    4.2. Tumor Type Market Share, 2024 & 2034
                    4.3. Segment Dashboard
                    4.4. U.S. Brain Tumor Market by Tumor Type Outlook
                    4.5. Market Size & Forecasts and Trend Analyses, 2024 to 2034 (Number of Patients Undergo Treatment Per Tumor Type)
                        4.5.1. Malignant
                            4.5.1.1. Malignant market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
                            4.5.1.2. Glioblastomas
                                4.5.1.2.1. Glioblastomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
                            4.5.1.3. Medulloblastomas
                                4.5.1.3.1. Medulloblastomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
                            4.5.1.4. Astrocytomas
                                4.5.1.4.1. Astrocytomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
                            4.5.1.5. Ependymomas
                                4.5.1.5.1. Ependymomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
                            4.5.1.6. Others
                                4.5.1.6.1. Others market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
                        4.5.2. Non-Malignant
                            4.5.2.1. Non-Malignant market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
                            4.5.2.2. Meningiomas
                                4.5.2.2.1. Meningiomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
                            4.5.2.3. Pituitary Adenomas
                                4.5.2.3.1. Pituitary Adenomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
                            4.5.2.4. Craniopharyngiomas
                                4.5.2.4.1. Craniopharyngiomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
                            4.5.2.5. Hemangioblastomas
                                4.5.2.5.1. Hemangioblastomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
                            4.5.2.6. Others
                                4.5.2.6.1. Others market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
Chapter 5. U.S. Brain Tumor Market: Treatment Type Estimates & Trend Analysis
                    5.1. Definitions and Scope
                    5.2. Treatment Type Market Share, 2024 & 2030
                    5.3. Segment Dashboard
                    5.4. U.S. Brain Tumor Market by Treatment Type Outlook
                    5.5. Malignant Tumor Treatment Type Market Size & Forecasts and Trend Analyses, 2024 to 2034 (Number of Patients per Treatment), USD Million in Terms of Number of Patients per Treatment, Volume (Unit)
                        5.5.1. Surgery
                            5.5.1.1. Surgery market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
                            5.5.1.2. Neurosurgical Instruments
                                5.5.1.2.1. Neurosurgical instruments market estimates and forecast 2024 to 2034 (USD Million)
                            5.5.1.3. Robotic Surgery Systems
                                5.5.1.3.1. Robotic surgery systems market estimates and forecast 2024 to 2034 (USD Million)
                            5.5.1.4. Interventional Device-Based Procedures
                                5.5.1.4.1. Interventional device-based procedures market estimates and forecast 2024 to 2034 (USD Million)
                            5.5.1.5. Endoscopes
                                5.5.1.5.1. Endoscopes market estimates and forecast 2024 to 2034 (USD Million)
                            5.5.1.6. Intraoperative Imaging Systems
                                5.5.1.6.1. Intraoperative imaging systems market estimates and forecast 2024 to 2034 (USD Million)
                            5.5.1.7. Others
                                5.5.1.7.1. Others market estimates and forecast 2024 to 2034 (USD Million)
                        5.5.2. Radiation Therapy
                            5.5.2.1. Radiation therapy market estimates and forecast 2024 to 2034 (USD Million)
                            5.5.2.2. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices
                                5.5.2.2.1. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices market estimates and forecast 2024 to 2034 (USD Million)
                                5.5.2.2.2. Linear Accelerators (LINAC)
                                    5.5.2.2.2.1. Linear Accelerators (LINAC) market estimates and forecast 2024 to 2034 (USD Million)
                                5.5.2.2.3. Gamma Knife Systems
                                    5.5.2.2.3.1. Gamma knife systems market estimates and forecast 2024 to 2034 (USD Million)
                                5.5.2.2.4. Proton radiosurgery
                                    5.5.2.2.4.1. Proton radiosurgery market estimates and forecast 2024 to 2034 (USD Million)
                            5.5.2.3. Internal radiation/Brachytherapy devices
                                5.5.2.3.1. Internal radiation/brachytherapy devices market estimates and forecast 2024 to 2034 (USD Million)
                        5.5.3. Interventional Device-Based Procedures
                            5.5.3.1. Interventional device-based procedures market estimates and forecast 2024 to 2034 (USD Million)
                            5.5.3.2. Embolization Devices
                                5.5.3.2.1. Embolization devices market estimates and forecast 2024 to 2034 (USD Million)
                                5.5.3.2.2. Liquid Embolic Agents
                                    5.5.3.2.2.1. Liquid embolic agents market estimates and forecast 2024 to 2034 (USD Million)
                                5.5.3.2.3. Microspheres
                                    5.5.3.2.3.1. Microspheres market estimates and forecast 2024 to 2034 (USD Million)
                            5.5.3.3. Tumor Ablation Devices
                                5.5.3.3.1. Tumor ablation devices market estimates and forecast 2024 to 2034 (USD Million)
                        5.5.4. Chemotherapy
                            5.5.4.1. Chemotherapy market estimates and forecast 2024 to 2034 (USD Million)
                        5.5.5. Targeted Therapy
                            5.5.5.1. Targeted therapy market estimates and forecast 2024 to 2034 (USD Million)
                        5.5.6. Tumor Treating Fields (TTF)
                            5.5.6.1. Tumor Treating Fields (TTF) market estimates and forecast 2024 to 2034 (USD Million)
                        5.5.7. Laser Interstitial Thermal Therapy (LITT)
                            5.5.7.1. Laser Interstitial Thermal Therapy (LITT) market estimates and forecast 2024 to 2034 (USD Million)
                        5.5.8. Surgically Targeted Radiation Therapy
                            5.5.8.1. Surgically targeted radiation therapy market estimates and forecast 2024 to 2034 (USD Million)
                        5.5.9. Catheter-Based Ultrasound Thermal Ablation
                            5.5.9.1. Catheter-based ultrasound thermal ablation market estimates and forecast 2024 to 2034 (USD Million)
                        5.5.10. Focused Ultrasound (FUS)
                            5.5.10.1. Focused Ultrasound (FUS) market estimates and forecast 2024 to 2034 (USD Million)
                        5.5.11. Low-Intensity Focused Ultrasound (LIFU)
                            5.5.11.1. Low-Intensity Focused Ultrasound (LIFU) market estimates and forecast 2024 to 2034 (USD Million)
                    5.6. Non-Malignant Tumor Treatment Type Market Size & Forecasts and Trend Analyses, 2024 to 2034 (Number of Patients per Treatment), USD Million in Terms of Number of Patients per Treatment, Volume (Unit)
                        5.6.1. Surgery
                            5.6.1.1. Surgery market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
                            5.6.1.2. Neurosurgical Instruments
                                5.6.1.2.1. Neurosurgical instruments market estimates and forecast 2024 to 2034 (USD Million)
                                5.6.1.2.2. Blade, Knife, Cutter & Scissors
                                    5.6.1.2.2.1. Blade, knife, cutter & scissors market estimates and forecast 2024 to 2034 (USD Million)
                                5.6.1.2.3. Dissector
                                    5.6.1.2.3.1. Dissector market estimates and forecast 2024 to 2034 (USD Million)
                                5.6.1.2.4. Drill & Perforator
                                    5.6.1.2.4.1. Drill & perforator market estimates and forecast 2024 to 2034 (USD Million)
                                5.6.1.2.5. Others
                                    5.6.1.2.5.1. Others market estimates and forecast 2024 to 2034 (USD Million)
                            5.6.1.3. Robotic Surgery Systems
                                5.6.1.3.1. Robotic surgery systems market estimates and forecast 2024 to 2034 (USD Million)
                            5.6.1.4. Endoscopes
                                5.6.1.4.1. Endoscopes market estimates and forecast 2024 to 2034 (USD Million)
                            5.6.1.5. Intraoperative Imaging Systems
                                5.6.1.5.1. Intraoperative imaging systems market estimates and forecast 2024 to 2034 (USD Million)
                            5.6.1.6. Others
                                5.6.1.6.1. Others market estimates and forecast 2024 to 2034 (USD Million)
                        5.6.2. Radiation Therapy
                            5.6.2.1. Radiation Therapy market estimates and forecast 2024 to 2034 (USD Million)
                            5.6.2.2. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices
                                5.6.2.2.1. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices market estimates and forecast 2024 to 2034 (USD Million)
                                5.6.2.2.2. Linear Accelerators (LINAC)
                                    5.6.2.2.2.1. Linear Accelerators (LINAC) market estimates and forecast 2024 to 2034 (USD Million)
                                5.6.2.2.3. Gamma Knife Systems
                                    5.6.2.2.3.1. Gamma knife systems market estimates and forecast 2024 to 2034 (USD Million)
                                5.6.2.2.4. Proton radiosurgery
                                    5.6.2.2.4.1. Proton radiosurgery market estimates and forecast 2024 to 2034 (USD Million)
                            5.6.2.3. Internal radiation/Brachytherapy Devices
                                5.6.2.3.1. Internal radiation/brachytherapy devices market estimates and forecast 2024 to 2034 (USD Million)
                        5.6.3. Other Monitoring Devices
                            5.6.3.1. Other monitoring devices market estimates and forecast 2024 to 2034 (USD Million)
Chapter 6. Competitive Landscape
                    6.1. Recent Developments & Impact Analysis, By Key Market Participants
                    6.2. Company/Competition Categorization
                        6.2.1. Innovators
                    6.3. Vendor Landscape
                        6.3.1. List of key distributors and channel partners
                        6.3.2. Key customers
                        6.3.3. Key company market share analysis, 2024
                        6.3.4. GT Medical Technologies, Inc.
                            6.3.4.1. Company overview
                            6.3.4.2. Financial performance
                            6.3.4.3. Product benchmarking
                            6.3.4.4. Strategic initiatives
                        6.3.5. Novocure
                            6.3.5.1. Company overview
                            6.3.5.2. Financial performance
                            6.3.5.3. Product benchmarking
                            6.3.5.4. Strategic initiatives
                        6.3.6. ZAP Surgical Systems, Inc.
                            6.3.6.1. Company overview
                            6.3.6.2. Financial performance
                            6.3.6.3. Product benchmarking
                            6.3.6.4. Strategic initiatives
                        6.3.7. Aesculap, Inc. - a B. Braun company
                            6.3.7.1. Company overview
                            6.3.7.2. Financial performance
                            6.3.7.3. Product benchmarking
                            6.3.7.4. Strategic initiatives
                        6.3.8. Accuray Incorporated
                            6.3.8.1. Company overview
                            6.3.8.2. Financial performance
                            6.3.8.3. Product benchmarking
                            6.3.8.4. Strategic initiatives
                        6.3.9. Carthera
                            6.3.9.1. Company overview
                            6.3.9.2. Financial performance
                            6.3.9.3. Product benchmarking
                            6.3.9.4. Strategic initiatives
                        6.3.10. Alpheus Medical Inc.
                            6.3.10.1. Company overview
                            6.3.10.2. Financial performance
                            6.3.10.3. Product benchmarking
                            6.3.10.4. Strategic initiatives
                        6.3.11. Alpha Tau Medical Ltd
                            6.3.11.1. Company overview
                            6.3.11.2. Financial performance
                            6.3.11.3. Product benchmarking
                            6.3.11.4. Strategic initiatives
                        6.3.12. Elekta
                            6.3.12.1. Company overview
                            6.3.12.2. Financial performance
                            6.3.12.3. Product benchmarking
                            6.3.12.4. Strategic initiatives
                        6.3.13. IMRIS Inc.
                            6.3.13.1. Company overview
                            6.3.13.2. Financial performance
                            6.3.13.3. Product benchmarking
                            6.3.13.4. Strategic initiatives
                        6.3.14. Medtronic
                            6.3.14.1. Company overview
                            6.3.14.2. Financial performance
                            6.3.14.3. Product benchmarking
                            6.3.14.4. Strategic initiatives
                        6.3.15. Monteris
                            6.3.15.1. Company overview
                            6.3.15.2. Financial performance
                            6.3.15.3. Product benchmarking
                            6.3.15.4. Strategic initiatives
                        6.3.16. Openwater
                            6.3.16.1. Company overview
                            6.3.16.2. Financial performance
                            6.3.16.3. Product benchmarking
                            6.3.16.4. Strategic initiatives
                        6.3.17. Acoustic MedSystems, Inc.
                            6.3.17.1. Company overview
                            6.3.17.2. Financial performance
                            6.3.17.3. Product benchmarking
                            6.3.17.4. Strategic initiatives
                        6.3.18. NaviFUS Corp
                            6.3.18.1. Company overview
                            6.3.18.2. Financial performance
                            6.3.18.3. Product benchmarking
                            6.3.18.4. Strategic initiatives
                        6.3.19. Insightec
                            6.3.19.1. Company overview
                            6.3.19.2. Financial performance
                            6.3.19.3. Product benchmarking
                            6.3.19.4. Strategic initiatives
                        6.3.20. Varian Medical Systems, Inc. (Siemens Healthineers)
                            6.3.20.1. Company overview
                            6.3.20.2. Financial performance
                            6.3.20.3. Product benchmarking
                            6.3.20.4. Strategic initiatives
                        6.3.21. RefleXion
                            6.3.21.1. Company overview
                            6.3.21.2. Financial performance
                            6.3.21.3. Product benchmarking
                            6.3.21.4. Strategic initiatives
                        6.3.22. MagnetTx Oncology Solutions Ltd.
                            6.3.22.1. Company overview
                            6.3.22.2. Financial performance
                            6.3.22.3. Product benchmarking
                            6.3.22.4. Strategic initiatives
                        6.3.23. NICO Corporation (Stryker)
                            6.3.23.1. Company overview
                            6.3.23.2. Financial performance
                            6.3.23.3. Product benchmarking
                            6.3.23.4. Strategic initiatives
                        6.3.24. Terumo Interventional Systems
                            6.3.24.1. Company overview
                            6.3.24.2. Financial performance
                            6.3.24.3. Product benchmarking
                            6.3.24.4. Strategic initiatives
                        6.3.25. Boston Scientific Corporation
                            6.3.25.1. Company overview
                            6.3.25.2. Financial performance
                            6.3.25.3. Product benchmarking
                            6.3.25.4. Strategic initiatives
                        6.3.26. Koninklijke Philips N.V.
                            6.3.26.1. Company overview
                            6.3.26.2. Financial performance
                            6.3.26.3. Product benchmarking
                            6.3.26.4. Strategic initiatives
                        6.3.27. IBA Worldwide
                            6.3.27.1. Company overview
                            6.3.27.2. Financial performance
                            6.3.27.3. Product benchmarking
                            6.3.27.4. Strategic initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 U.S. Brain Tumor market, by Treatment Type 2024 - 2034 (USD Million)
Table 4 U.S. Brain Tumor market, by Tumor Type 2024 - 2034 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. brain tumor market: Market snapshot
Fig. 9 U.S. brain tumor market: Market segmentation
Fig. 10 U.S. brain tumor market: Strategy framework
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 U.S. brain tumor market driver impact
Fig. 14 U.S. brain tumor market restraint impact
Fig. 15 U.S. brain tumor market porter’s five forces analysis
Fig. 16 U.S. brain tumor market PESTEL analysis
Fig. 17 U.S. brain tumor market segment dashboard
Fig. 18 U.S. brain tumor market: Tumor type movement Analysis
Fig. 19 Malignant brain tumor market estimates and forecast, 2024 - 2034 (USD Million)
Fig. 20 Non-malignant brain tumor market estimates and forecast, 2024 - 2034 (USD Million)
Fig. 21 U.S. brain tumor market: Treatment type (malignant) movement Analysis
Fig. 22 Surgery market estimates and forecast, 2024 - 2034 (USD Million)
Fig. 23 Radiation therapy market estimates and forecast, 2024 - 2034 (USD Million)
Fig. 24 Interventional device-based procedures market estimates and forecast, 2024 - 2034 (USD Million)
Fig. 25 Chemotherapy market estimates and forecast, 2024 - 2034 (USD Million)
Fig. 26 Targeted therapy market estimates and forecast, 2024 - 2034 (USD Million)
Fig. 27 Tumor Treating Fields (TTF) market estimates and forecast, 2024 - 2034 (USD Million)
Fig. 28 Laser Interstitial Thermal Therapy (LITT) market estimates and forecast, 2024 - 2034 (USD Million)
Fig. 29 Surgically targeted radiation therapy market estimates and forecast, 2024 - 2034 (USD Million)
Fig. 30 Catheter-based ultrasound thermal ablation market estimates and forecast, 2024 - 2034 (USD Million)
Fig. 31 Focused Ultrasound (FUS) market estimates and forecast, 2024 - 2034 (USD Million)
Fig. 32 Low-Intensity Focused Ultrasound (LIFU) market estimates and forecast, 2024 - 2034 (USD Million)
Fig. 33 U.S. brain tumor market: Treatment type (non-malignant) movement Analysis
Fig. 34 Surgery market estimates and forecast, 2024 - 2034 (USD Million)
Fig. 35 Radiation therapy market estimates and forecast, 2024 - 2034 (USD Million)
Fig. 36 Other monitoring devices market estimates and forecast, 2024 - 2034 (USD Million)